HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy.

AuthorsRyoji Takada, Kazuyoshi Ohkawa, Yoji Kukita, Kenji Ikezawa, Nobuyasu Fukutake, Yutaro Abe, Toshihiro Imai, Ryosuke Kiyota, Takatoshi Nawa, Takuo Yamai, Reiko Ashida, Kikuya Kato, Kazuhiro Katayama
JournalPancreas (Pancreas) Vol. 49 Issue 9 Pg. e93-e95 (10 2020) ISSN: 1536-4828 [Electronic] United States
PMID33003099 (Publication Type: Letter)
Chemical References
  • 130-nm albumin-bound paclitaxel
  • Albumins
  • Biomarkers, Tumor
  • Circulating Tumor DNA
  • KRAS protein, human
  • Deoxycytidine
  • Proto-Oncogene Proteins p21(ras)
  • Paclitaxel
  • Gemcitabine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Albumins (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Biomarkers, Tumor (blood, genetics)
  • Circulating Tumor DNA (genetics)
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Disease Progression
  • Female
  • High-Throughput Nucleotide Sequencing (methods)
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Paclitaxel (administration & dosage)
  • Pancreatic Neoplasms (diagnosis, drug therapy, genetics)
  • Prognosis
  • Proto-Oncogene Proteins p21(ras) (genetics)
  • Survival Analysis
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: